Frequently Asked Question
The global Cell isolation cell separation market was valued at USD 4.1 Billion in 2022.
The Cell isolation cell separation market is expected to grow at a CAGR of 13.70% between 2023 and 2030, reaching USD 10.0 Billion in 2030.
In 2022, the human cell segment had the highest revenue share of roughly 45.50%.
In 2022, the research laboratories and institutions section accounted for more than 45% of total income
The Instruments segment will likely exhibit the fastest CAGR during the forecast period.
North America will have around 42% of the cell isolation/cell separation market in 2022.
The top players include Thermo Fisher Scientific, Inc.; Becton, Dickinson and Company; Danaher (Beckman Coulter, Inc.; Cytiva). Other major players include Terumo Corporation; STEMCELL Technologies Inc.; Bio-Rad Laboratories, Inc.; Merck KGaA.
Chronic diseases are growing increasingly widespread, and the demand for clinical trials and research is increasing as the senior population grows is the major market drivers.
Cell Isolation/Cell Separation Instruments and Reagents are Expensive, and Cell Isolation/Cell Separation Techniques Lack Standardization and Reproducibility are the major market restraints.
Cell isolation/cell separation is gaining prominence in cancer research and diagnostics, and investments in stem cell research and regenerative medicine are increasing are the major opportunities in the Cell isolation cell separation industry.